Vall d'Hebron leads an international phase III clinical trial demonstrating the efficacy of atogepant, an oral drug for the prevention of chronic migraine

by Vall d’Hebron

Atogepant is the first oral drug that can be useful for patients with chronic migraine, which makes it easier to access, provides flexibility in drug administration and is easier to store, since injec...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Ona Therapeutics Raises $86.6 Million Se...

by Ysios Capital

Proceeds to support clinical development of lead first-in-class progra...

Photos Stream